MICA: The North West England MRC Fellowship Scheme in Clinical Pharmacology and Therapeutics
Lead Research Organisation:
University of Liverpool
Department Name: Institute of Translational Medicine
Abstract
Clinical pharmacologists are physicians and scientists whose focus is developing and understanding existing and new drug therapies; they work in a variety of settings in academia, the NHS, industry and government. In the clinical setting, they work directly with patients, participate in trials, and investigate how patients respond to drugs, including why certain patients develop side effects to drugs. The total number of academic clinical pharmacologists trained in the UK is small, and there is an imperative to continue to train more clinical pharmacologists and other specialists with expertise in clinical pharmacology who can work between academia, healthcare and industry. In 2010, the Government recognised that the provision of high quality-care and better interaction with Industry requires clinicians to be familiar with the relevant practices in clinical pharmacology. The universities of Liverpool and Manchester, in collaboration with industry partners, were awarded funding from the MRC to address this unmet need in clinical pharmacology: The North West England MRC Clinical Research Training Fellowship Programme in Clinical Pharmacology and Therapeutics. This programme has allowed 13 clinical fellows (high flying trainee doctors), rigorously selected from across all medical specialties e.g. dermatology, rheumatology, paediatrics etc., to study for PhDs on a variety of clinical pharmacology related research topics such as drug safety and stratified medicine - matching the right drug to the right patient. In addition to their research work the fellows received without walls training with industry and modular training in key aspects of clinical pharmacology. The programme has been a tremendous success with 56 scientific journal publications, 21 conference presentations, 13 prizes and interactions with 61 NHS Trusts. All fellows will also get a PhD.
We now wish to renew the scheme with the MRC and with 4 industry partners - Lilly, Novartis, Roche and UCB Pharma, to appoint 13 more fellows. The previous successful format and structure will be retained as will joint leadership from the two universities. Refinements to the programme include: increasing the number of industry partners thereby allowing us to cover more therapeutic areas including cancer; lengthening of the recruitment process to give potential fellows, their supervisors and industry representatives more time to develop research projects with strong alignment; identification of a lead industry partner for each fellow from the beginning of the programme to develop a partnership from the outset; ensuring, where possible, that fellows can spend up to one year with the industry partner at their site(s) performing different aspects of their project. These changes will enhance fellows' training with industry, and also increase the input provided by industry in individual projects. There will be very strong patient and public engagement (as in the current scheme) with involvement of patients in the planning of research proposals, a number of public lectures and involvement of fellows at events such as the Manchester Science Spectacular.
The Fellowship Programme will go some way to producing academics with expertise in clinical pharmacology and helping to optimise the safe, targeted prescribing of existing drugs and the development of new therapies for human disease.
We now wish to renew the scheme with the MRC and with 4 industry partners - Lilly, Novartis, Roche and UCB Pharma, to appoint 13 more fellows. The previous successful format and structure will be retained as will joint leadership from the two universities. Refinements to the programme include: increasing the number of industry partners thereby allowing us to cover more therapeutic areas including cancer; lengthening of the recruitment process to give potential fellows, their supervisors and industry representatives more time to develop research projects with strong alignment; identification of a lead industry partner for each fellow from the beginning of the programme to develop a partnership from the outset; ensuring, where possible, that fellows can spend up to one year with the industry partner at their site(s) performing different aspects of their project. These changes will enhance fellows' training with industry, and also increase the input provided by industry in individual projects. There will be very strong patient and public engagement (as in the current scheme) with involvement of patients in the planning of research proposals, a number of public lectures and involvement of fellows at events such as the Manchester Science Spectacular.
The Fellowship Programme will go some way to producing academics with expertise in clinical pharmacology and helping to optimise the safe, targeted prescribing of existing drugs and the development of new therapies for human disease.
Technical Summary
There is an imperative to train more clinical pharmacologists who can work between UK academia, healthcare and industry. This was acknowledged by the Office of Life Science in 2010, which led to the award of the North West England MRC Clinical Research Training Fellowship Programme in Clinical Pharmacology and Therapeutics (CPT). The Programme has trained 13 high-calibre clinical Fellows, from a variety of specialties, to PhD level. The Fellowships have resulted in an impressive list of outputs including publications, further grant funding and active patient and public engagement. Most have graduated to academic posts. We now wish to renew the programme. The scheme is strengthened by involving 4 major pharmaceutical companies (Lilly, Novartis, Roche and UCB Pharma) who will contribute both in cash and in kind. These industry partners will provide without walls training for the Fellows, enhanced by increasing the potential for alignment between their therapeutic areas and the interests of the Fellows. All Fellows will receive modular training in CPT. We will continue with a robust two-stage recruitment process (with MRC input), but will modify it by increasing the time-interval between the two stages to allow for more input from Industry into individual projects. The Fellows will have an industry co-supervisor and spend 3-12 months at partner sites. The thematic areas chosen are consistent with: (a) the academic strengths of the two Universities; and (b) the significant investments from the MRC into the MRC Centre for Drug Safety Science, and the Stratified Medicine and Molecular Pathology initiatives.
Planned Impact
Clinical Pharmacology is a speciality vital for UK healthcare and industry and should be at the very heart of the drug development process. The beneficiaries are:
1.Academia
- Publishing in high-impact journals will ensure that the science-base grows in the pharmacological responses to medicines (1-5 yr)
- The Fellowship scheme will improve our ability to bring together diverse experts in order to enhance our specific research programmes and address the need for more medically qualified clinical pharmacologists (1-5 yr)
- Other national/ international academics will gain from collaborative links with Fellows, either from access to clinical samples, access to cross-cutting technologies, or access to intellectual expertise (1-5 yr)
- The scheme will produce 'rounded' clinical pharmacologists with sought-after skill-sets, who will make a valuable and practical contribution to the continued growth of this cross-disciplinary medical research activity in the UK (5-7 yr)
- Training of these Fellows will enhance experimental medicines capabilities within the UK, an area identified as vital for future innovation and economic growth (5-7 yr)
2.Health Care Providers
- The scheme will increase capacity in Clinical Pharmacology and Therapeutics and help to reduce a well-documented critical skills gap in the NHS (5-7 yr)
- Newly-trained Fellows will promote and support more effective prescribing within the NHS (5+ yr)
- Data produced by Fellows will inform prognostic and diagnostic testing strategies that will lead to safer and more cost-effective personalisation of therapies (5+ yr)
- Scientific outputs from Fellows will improve the benefit-risk profile of medicines and reduce the financial burden associated with adverse drug reactions or lack of efficacy (5+ yr)
- Fellows will enhance capabilities for early phase trials within NHS organisations through the development of clinical research facilities and interactions with Industry, ultimately improving access to novel medicines for patients (5+ yr)
- Fellows will increase capabilities in precision medicine in the UK NHS, an area vital for future healthcare (5+ yr)
3.Pharmaceutical Industry
- The skills gap in clinical pharmacology is acutely felt in the pharmaceutical sector and so the capacity-building aspect of the scheme will lead to an innovative partnership between academic and pharma, integrating academic expertise from early development of drugs through to postmarketing (5-7 yr)
- The "without-walls" focus of training for the Clinical Fellows will help to build new collaborations and drive novel scientific plans between pharma, the NHS and academia (1-5 yr)
- Scientific outputs from Fellows will be used to develop drugs with better benefit-risk profiles, with associated reputational and economic benefits to the industry (5+ yr)
4.Diagnostics Sector
- There will be new opportunities for the commercialisation of diagnostic and prognostic testing strategies leading to an improvement in the benefit:risk of drugs, especially in complex patient populations, with knock-on economic benefits to the sector (5+ yr)
- It will enhance the development of diagnostics for precision medicine (5+ yr)
5.Regulatory Authorities
- Fellows' scientific outputs will better inform drug regulators and will thereby contribute towards better evidence-based policy making at a global level (5+ yr)
- It will increase the number of experts in clinical pharmacology to act on advisory bodies for the regulators, thereby enhancing national and international influence (5+ yr)
6.Patients and the General Public
- Improving the benefit-risk of existing and new medicines will clearly have a major impact on enhancement of the clinical care of patients, improving clinical outcome and quality of life (5+ yr)
- The publics interest in drug safety and precision medicine is high and Fellows will educate the public in their perception of the benefits and risks associated with medicines (1-5 yr)
1.Academia
- Publishing in high-impact journals will ensure that the science-base grows in the pharmacological responses to medicines (1-5 yr)
- The Fellowship scheme will improve our ability to bring together diverse experts in order to enhance our specific research programmes and address the need for more medically qualified clinical pharmacologists (1-5 yr)
- Other national/ international academics will gain from collaborative links with Fellows, either from access to clinical samples, access to cross-cutting technologies, or access to intellectual expertise (1-5 yr)
- The scheme will produce 'rounded' clinical pharmacologists with sought-after skill-sets, who will make a valuable and practical contribution to the continued growth of this cross-disciplinary medical research activity in the UK (5-7 yr)
- Training of these Fellows will enhance experimental medicines capabilities within the UK, an area identified as vital for future innovation and economic growth (5-7 yr)
2.Health Care Providers
- The scheme will increase capacity in Clinical Pharmacology and Therapeutics and help to reduce a well-documented critical skills gap in the NHS (5-7 yr)
- Newly-trained Fellows will promote and support more effective prescribing within the NHS (5+ yr)
- Data produced by Fellows will inform prognostic and diagnostic testing strategies that will lead to safer and more cost-effective personalisation of therapies (5+ yr)
- Scientific outputs from Fellows will improve the benefit-risk profile of medicines and reduce the financial burden associated with adverse drug reactions or lack of efficacy (5+ yr)
- Fellows will enhance capabilities for early phase trials within NHS organisations through the development of clinical research facilities and interactions with Industry, ultimately improving access to novel medicines for patients (5+ yr)
- Fellows will increase capabilities in precision medicine in the UK NHS, an area vital for future healthcare (5+ yr)
3.Pharmaceutical Industry
- The skills gap in clinical pharmacology is acutely felt in the pharmaceutical sector and so the capacity-building aspect of the scheme will lead to an innovative partnership between academic and pharma, integrating academic expertise from early development of drugs through to postmarketing (5-7 yr)
- The "without-walls" focus of training for the Clinical Fellows will help to build new collaborations and drive novel scientific plans between pharma, the NHS and academia (1-5 yr)
- Scientific outputs from Fellows will be used to develop drugs with better benefit-risk profiles, with associated reputational and economic benefits to the industry (5+ yr)
4.Diagnostics Sector
- There will be new opportunities for the commercialisation of diagnostic and prognostic testing strategies leading to an improvement in the benefit:risk of drugs, especially in complex patient populations, with knock-on economic benefits to the sector (5+ yr)
- It will enhance the development of diagnostics for precision medicine (5+ yr)
5.Regulatory Authorities
- Fellows' scientific outputs will better inform drug regulators and will thereby contribute towards better evidence-based policy making at a global level (5+ yr)
- It will increase the number of experts in clinical pharmacology to act on advisory bodies for the regulators, thereby enhancing national and international influence (5+ yr)
6.Patients and the General Public
- Improving the benefit-risk of existing and new medicines will clearly have a major impact on enhancement of the clinical care of patients, improving clinical outcome and quality of life (5+ yr)
- The publics interest in drug safety and precision medicine is high and Fellows will educate the public in their perception of the benefits and risks associated with medicines (1-5 yr)
Organisations
- University of Liverpool (Lead Research Organisation, Project Partner)
- The Clatterbridge Cancer Centre NHS Foundation Trust (Collaboration)
- Protypia (Collaboration)
- Definiens AG (Collaboration)
- Leeds Teaching Hospitals NHS Trust (Collaboration)
- Medical University of Vienna (Collaboration)
- Sengenics (Collaboration)
- University Hospital Zürich (Collaboration)
- THE CHRISTIE NHS FOUNDATION TRUST (Collaboration)
- John Radcliffe Hospital (Collaboration)
- UNIVERSITY OF OXFORD (Collaboration)
- Belfast City Hospital (Collaboration)
- NEWCASTLE UPON TYNE HOSPITALS NHS FOUNDATION TRUST (Collaboration)
- Roche Pharmaceuticals (Collaboration)
- Sheffield Teaching Hospitals NHS Foundation Trust (Collaboration)
- UNIVERSITY OF LIVERPOOL (Collaboration)
- KING'S COLLEGE LONDON (Collaboration)
- University of Manchester (Project Partner)
- Novartis (United Kingdom) (Project Partner)
- Eli Lilly (United Kingdom) (Project Partner)
- Roche (United Kingdom) (Project Partner)
- UCB Pharma (United Kingdom) (Project Partner)
Publications
Haragan A
(2019)
DLL3, a new biomarker for neuroendocrine tumors of the lung
Haragan A
(2020)
Accelerated instability testing reveals quantitative mass spectrometry overcomes specimen storage limitations associated with PD-L1 immunohistochemistry.
in Laboratory investigation; a journal of technical methods and pathology
Haragan A
(2019)
Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response.
in Lung cancer (Amsterdam, Netherlands)
Haragan A
(2019)
Biomarkers in NSCLC: a pathologist's insight into PD-L1 and TMB
Haragan A
(2020)
Immunohistochemistry for prediction of response to immunotherapy
in Diagnostic Histopathology
Haragan A
(2018)
P1.04-24 Digital Core Needle-Biopsy to Assess PD-L1 Expression in Non-Small Cell Lung Cancer: Optimal Sampling and Need for Re-Biopsy
in Journal of Thoracic Oncology
Haragan A
(2020)
High expression of PD-L1 by pulmonary adenocarcinoma metastatic to body cavities; artefact or biology?
in Lung Cancer
Hammond S
(2021)
T cell mediated hypersensitivity to previously tolerated iodinated contrast media precipitated by introduction of atezolizumab.
in Journal for immunotherapy of cancer
Hammond S
(2022)
Checkpoint Inhibition Reduces the Threshold for Drug-Specific T-Cell Priming and Increases the Incidence of Sulfasalazine Hypersensitivity.
in Toxicological sciences : an official journal of the Society of Toxicology
Gosney JR
(2020)
Programmed death ligand 1 expression in EBUS aspirates of non-small cell lung cancer: Is interpretation affected by type of fixation?
in Cancer cytopathology
Gosney J.
(2018)
PD-L1 Expression in EBUS-Guided Cytology Specimens of Non-Small Cell Lung Cancer is Not Affected by Type of Fixation: A Study of Matched Pairs
in JOURNAL OF THORACIC ONCOLOGY
Gosney J
(2018)
ESMO handbook of Immuno-Oncology
Gosney J
(2018)
Problem solving in Cancer immunotherapy
Gibani MM
(2019)
Investigation of the role of typhoid toxin in acute typhoid fever in a human challenge model.
in Nature medicine
Farrington N
(2022)
Pharmacodynamics of Meropenem and Tobramycin for Neonatal Meningoencephalitis: Novel Approaches to Facilitate the Development of New Agents to Address the Challenge of Antimicrobial Resistance.
in Antimicrobial agents and chemotherapy
Elwin F
(2020)
PD-L1 expression in non-small cell lung cancer according to specimen type; a retrospective study of over 2,000 cases
in Lung Cancer
Eagle GL
(2021)
Assessing technical and biological variation in SWATH-MS-based proteomic analysis of chronic lymphocytic leukaemia cells.
in Scientific reports
Dyball S
(2022)
Ianalumab in Sjögren's syndrome: what can we learn from lupus trials?
in Lancet (London, England)
Dyball S
(2021)
Lupus clinical trial eligibility in a real-world setting: results from the British Isles Lupus Assessment Group-Biologics Register (BILAG-BR).
in Lupus science & medicine
Dyball S
(2022)
Predicting progression from undifferentiated connective tissue disease to definite connective tissue disease: A systematic review and meta-analysis.
in Autoimmunity reviews
Darlow CA
(2022)
Flomoxef and fosfomycin in combination for the treatment of neonatal sepsis in the setting of highly prevalent antimicrobial resistance.
in The Journal of antimicrobial chemotherapy
Darlow CA
(2022)
Assessment of flomoxef combined with amikacin in a hollow-fibre infection model for the treatment of neonatal sepsis in low- and middle-income healthcare settings.
in The Journal of antimicrobial chemotherapy
Darlow CA
(2021)
Amikacin Combined with Fosfomycin for Treatment of Neonatal Sepsis in the Setting of Highly Prevalent Antimicrobial Resistance.
in Antimicrobial agents and chemotherapy
Darlow CA
(2021)
Potential Antibiotics for the Treatment of Neonatal Sepsis Caused by Multidrug-Resistant Bacteria.
in Paediatric drugs
Darlow CA
(2022)
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales.
in The Journal of antimicrobial chemotherapy
Darlow CA
(2022)
Flomoxef for neonates: extending options for treatment of neonatal sepsis caused by ESBL-producing Enterobacterales-authors' response.
in The Journal of antimicrobial chemotherapy
Darlow CA
(2020)
Microbial aetiology of brain abscess in a UK cohort: Prominent role of Streptococcus intermedius.
in The Journal of infection
Darlow C
(2023)
Development and application of neonatal physiology-based pharmacokinetic models of amikacin and fosfomycin to assess pharmacodynamic target attainment
in CPT: Pharmacometrics & Systems Pharmacology
Cheung VTF
(2020)
Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
in British journal of cancer
Chatterjee A
(2018)
Quantifying drivers of antibiotic resistance in humans: a systematic review.
in The Lancet. Infectious diseases
Chan BKY
(2021)
Pharmacological Activation of Nrf2 Enhances Functional Liver Regeneration.
in Hepatology (Baltimore, Md.)
Chan BKY
(2022)
Surgical management of suspected gallbladder cancer: The role of intraoperative frozen section for diagnostic confirmation.
in Journal of surgical oncology
Boyd SE
(2020)
Validating a prediction tool to determine the risk of nosocomial multidrug-resistant Gram-negative bacilli infection in critically ill patients: A retrospective case-control study.
in Journal of global antimicrobial resistance
Boyd SE
(2017)
Combination therapy for carbapenemase-producing Entero-bacteriaceae: INCREMENT-al effect on resistance remains unclear.
in The Lancet. Infectious diseases
Boyd SE
(2022)
OXA-48-Like ß-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline.
in Antimicrobial agents and chemotherapy
Boyd S
(2020)
Metallo-ß-Lactamases: Structure, Function, Epidemiology, Treatment Options, and the Development Pipeline
in Antimicrobial Agents and Chemotherapy
Bhogal T
(2021)
Haematological malignancy and nosocomial transmission are associated with an increased risk of death from COVID-19: results of a multi-center UK cohort.
in Leukemia & lymphoma
Best J
(2021)
Coronavirus Disease 2019: the Pivotal Role of UK Clinical Oncology and the UK Coronavirus Cancer Monitoring Project.
in Clinical oncology (Royal College of Radiologists (Great Britain))
Asfour L
(2023)
Global Guidelines in Dermatology Mapping Project (GUIDEMAP): a systematic review of alopecia areata clinical practice guidelines
in Clinical and Experimental Dermatology
Anil I
(2020)
The UK Coronavirus Cancer Monitoring Project: protecting patients with cancer in the era of COVID-19
in The Lancet Oncology
Andrew R. Pettitt
(2020)
Lenalidomide, dexamethasone and alemtuzumab or ofatumumab in high-risk chronic lymphocytic leukaemia: final results of the NCRI CLL210 trial
in Haematologica
Ali Z
(2021)
Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis.
in Expert review of clinical immunology
Al-Janabi A
(2022)
Paradoxical eczema in patients with psoriasis receiving biologics: a case series.
in Clinical and experimental dermatology
Al-Janabi A
(2023)
Integrated proteomics and genomics analysis of paradoxical eczema in psoriasis patients treated with biologics
in Journal of Allergy and Clinical Immunology
Al-Janabi A
(2023)
The effect of immunomodulators on seroconversion after BNT162b2 and AZD1222 vaccines in patients with immune-mediated inflammatory diseases: a prospective cohort study.
in The British journal of dermatology
Al-Janabi A
(2023)
Atopic Polygenic Risk Score Is Associated with Paradoxical Eczema Developing in Patients with Psoriasis Treated with Biologics.
in The Journal of investigative dermatology
| Description | Audit and Research Lead, Roux Group Executive Committee, Association of Upper GI Surgeons of Great Britain and Ireland (AUGIS) |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Impact | "Enhancing Education, Research and Training" The Roux Group is a UK-wide, trainee-led collaborative aimed at developing and enhancing the existing training, education and research opportunities available to trainees in all branches of upper gastrointestinal surgery (oesophagogastric, hepatobiliary, pancreatic, and bariatric surgery). We represent the trainee arm of AUGIS. https://www.rouxgroup.org.uk/ |
| URL | https://www.rouxgroup.org.uk/ |
| Description | Co-Chair of the Royal College of Physicians in Edinburgh Trainee and Members Committee - Anna Olsson-Brown |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | As co-chair of the CPE TMC Anna is involved in all of the committees activities. This includes a representation role both nationally and internationally. Anna represents the RCPE at federation and Academy of Royal Colleges. In addition to this the college are involved in education, careers and communication with junior doctors, sevior doctors, members of alied health professionals and the general public |
| URL | https://www.rcpe.ac.uk/college/trainees-and-members-committee |
| Guideline Title | Emergency Guideline: Acute management of the endocrine complications of checkpoint inhibitor therapy |
| Description | Development of guidelines for the management of endocrine disorders secondary to immuno-oncology checkpoint inhibition - Anna Olsson-Brown |
| Geographic Reach | National |
| Policy Influence Type | Citation in clinical guidelines |
| Description | Elected Member of the Trainees and Members Committee at the Royal College of Physicians in Edinburgh (Dr Anna Olsson-Brown) |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | The committee has three main foci - Representation at National level pertaining to post-graduate training and representation; Education resulting in the composition and delivery of national lecture series "Evening Medical Updates" and a yearly symposium "Medical Trainees Conference" and Careers and Communication which is focused on the development and support of post graduate training within the medical specialties. |
| Description | Expert Panel Meeting for UK NEQAS PD-L1 Scheme |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Impact | UK NEQAS is a national voluntary scheme that pathology departments and laboratories across the UK sign up to for quality assurance matters. I have twice sat on the panel as an expert at interpretation of PD-L1 (programmed death-ligand 1) immunohistochemistry to assess the quality of laboratories staining, antibody retrieval for use as a clinically diagnostic tool, and their material as chosen to represent controls for the same. This information is fedback to each laboratory with advice as to how they might improve in an effort to standardise, as far as possible, the PD-L1 reporting quality across the UK, and ensure a minimum quality is reached by every involved diagnostic lab. |
| URL | https://ukneqas.org.uk |
| Description | Expert Panel Meeting for UK NEQAS PD-L1 Scheme |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Impact | Ongoing member of Expert Panel for PD-L1 immunohistochemistry as part of UKNEQAS. |
| Description | JRCPTB Management and Policy (MAP) Board Member - Anna Olsson-Brown |
| Geographic Reach | National |
| Policy Influence Type | Participation in a guidance/advisory committee |
| Impact | Anna acts as one of the trainee representatives at the JRCPTB management and policy board. The remit of the board is to address all educational issues pertaining to the medical training of doctors in physicianly specialities including those in academic training posts and those training LTFT. |
| Description | Lecturing at Molecular Diagnostics School, Vienna, Austria 2019 |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Lecturing to professional medical practitioners and pathologists for molecular diagnostics in immuno-oncology with practical guidance on how to perform adequate testing in the routine clinical setting. |
| URL | https://www.personalized-medicine.at/die-oeppm/news/detail/molecular-diagnostics-training-school-ima... |
| Description | Lecturing at Molecular Diagnostics Training School, Vienna, Austria, 2020. |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Lecturing to professional medical practitioners and pathologists for molecular diagnostics in immuno-oncology with practical guidance on how to perform adequate testing in the routine clinical setting. |
| URL | https://www.meduniwien.ac.at/hp/pathologie/news/singleview/?tx_ttnews%5Btt_news%5D=5111&cHash=a3b9cd... |
| Description | Member of LHP Oncology Education Group (Dr Anna Olsson-Brown) |
| Geographic Reach | Local/Municipal/Regional |
| Policy Influence Type | Membership of a guideline committee |
| Impact | This group has contributed to a number of training days (Regional and National) and supports an Acute Oncology Master level module at the University of Liverpool. The next educational session pertains to Oncology and Genomics. |
| Description | Member of UKONS Oncology Working Group (Dr Anna Olsson-Brown) |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Description | Participation in a advisory committee - Dr Boyd is a member of the JRCPTB Specialty Advisory Committee for Infection Training in the UK (2016-2020) |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | My involvement in this national committee has allowed me to be involved in developing and troubleshooting the implementation of a national curriculum for infection trainees, which aims to improve the education and skills of the workforce in addition to improving the efficiency and effectiveness of public service delivery. |
| Description | Presentation and Q&A session at Diagnostics Summit (AZ funded) |
| Geographic Reach | National |
| Policy Influence Type | Influenced training of practitioners or researchers |
| Impact | Talk and Q&A session with medical professionals (largely pathologists) on the practical considerations on how to use and manage bio-specimens for effective use in predictive immunohistochemistry immune-landscape profiling with PD-L1 expression. |
| Description | Steering Group member leading to the publication of national guidelines - UKONS Inital Management Guidelines |
| Geographic Reach | National |
| Policy Influence Type | Membership of a guideline committee |
| Impact | This guideline has unified a national approach to the management of immune related adverse events as a result of oncological immunotherapies streamlining management and optimising patient outcomes from toxicity |
| URL | https://www.nwcscnsenate.nhs.uk/files/9815/2759/2181/UKONS_AO_management_guidelines_-_Rev._March_202... |
| Description | Additional funding for further hollow fibre infection model experiments to inform neonatal sepsis regimens |
| Amount | £100,006 (GBP) |
| Organisation | Global Antibiotic Research and Development Partnership |
| Sector | Charity/Non Profit |
| Country | Switzerland |
| Start | 12/2020 |
| End | 07/2021 |
| Description | BTOG Scholarship Bursary |
| Amount | £300 (GBP) |
| Organisation | British Thoracic Oncology Group |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2019 |
| End | 01/2019 |
| Description | British Association of Dermatologists - American Academy of Dermatology |
| Amount | £2,000 (GBP) |
| Organisation | British Association of Dermatologists (BAD) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | |
| Description | British Association of Dermatologists and Dowling Club |
| Amount | £1,000 (GBP) |
| Organisation | British Association of Dermatologists (BAD) |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 04/2019 |
| End | 04/2019 |
| Description | European Academy of Dermatology and Venereology - Travel Grant |
| Amount | € 1,000 (EUR) |
| Organisation | European Academy of Dermatology and Venereology |
| Sector | Charity/Non Profit |
| Country | Switzerland |
| Start | 09/2018 |
| End | 09/2018 |
| Description | European Society of Medical Oncology Merit Award |
| Amount | € 400 (EUR) |
| Organisation | European Society of Medical Oncology (ESMO) |
| Sector | Charity/Non Profit |
| Country | Switzerland |
| Start | 12/2018 |
| End | 12/2018 |
| Description | Liverpool Cancer Research Institute (LCRI) Research Development Fund |
| Amount | £19,955 (GBP) |
| Organisation | University of Liverpool |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 05/2022 |
| End | 05/2023 |
| Description | MRC Discovery Medicine North (DiMeN) Flexible Funding Grant |
| Amount | £2,950 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 11/2018 |
| End | 02/2019 |
| Description | MRC Festival Establishment Award |
| Amount | £1,500 (GBP) |
| Funding ID | MRC Festival Establishment Award |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 01/2020 |
| Description | MRC Flexible Supplement Grant |
| Amount | £2,430 (GBP) |
| Organisation | Medical Research Council (MRC) |
| Sector | Public |
| Country | United Kingdom |
| Start | 09/2018 |
| End | 12/2018 |
| Description | Ronnie Austin Bursary |
| Amount | £5,410 (GBP) |
| Organisation | University of Liverpool |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 01/2022 |
| Description | THE CLATTERBRIDGE CANCER CENTRE NHS FOUNDATION TRUST (UK) Research Funding Scheme 2019 |
| Amount | £20,000 (GBP) |
| Organisation | The Clatterbridge Cancer Centre NHS Foundation Trust |
| Sector | Public |
| Country | United Kingdom |
| Start | 05/2020 |
| End | 05/2022 |
| Description | Technology Directorate, University of Liverpool |
| Amount | £7,125 (GBP) |
| Organisation | University of Liverpool |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 06/2019 |
| End | 05/2020 |
| Description | University of Liverpool Centre for Proteome Research MALDI Imaging Competition |
| Amount | £2,000 (GBP) |
| Organisation | University of Liverpool |
| Sector | Academic/University |
| Country | United Kingdom |
| Start | 07/2019 |
| End | 01/2020 |
| Description | Wellcome Trust Public Engagement Grant (Umair Khan & Jing Xu) |
| Amount | £900 (GBP) |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 02/2019 |
| End | 09/2019 |
| Description | Wellcome trust strategic support funds |
| Amount | £15,000 (GBP) |
| Funding ID | 163504 |
| Organisation | Wellcome Trust |
| Sector | Charity/Non Profit |
| Country | United Kingdom |
| Start | 01/2020 |
| End | 12/2020 |
| Title | HYST Sample collection in Immunotherapy patients |
| Description | My research project has led to the development of a database and biobank of samples collected from patients recieving immunotherapies and from those experiencing toxicity. This has occurred within the study entitled: A Mechanistic Investigation into Drug and Chemical induced hypersensitivity reactions REC Ref 12/NW/0525. Samples and clinical data is supported by CRF collection. Arms of the study include: Longitudinal Cohort Study - Pretreatment samples and then periodic samples over 4 months Longitudinal Case/Control Study - Recruited at the time of an immune related adverse events secondary to checkpoint inhibitors and periodic sampling following this End Organ studies - Three arms with blood and tissue samples taken in a paired fashion at the point of toxicity. Arms include Thyroiditis (Double pass FNA), Skin biopsy (6mm punch biopsy) and colitis (12 bite biopsies) |
| Type Of Material | Database/Collection of data |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | The outputs from this database and samples is currently being established with work ongoing |
| Title | MolGen Immunotherapy |
| Description | Samples for DNA extraction and clinical data collection associated with CRF and electronic database in patients receiving immunotherapy. Patients are collected and categorised by the experience of immune related adverse events or no evidence of toxicity. This is conducted under the Molecular Genetics of Adverse Drug Reaction Study Ethics Research Number 09/H1005/28. Recruitment is available nationally and is portfolio adopted. |
| Type Of Material | Database/Collection of data |
| Year Produced | 2017 |
| Provided To Others? | Yes |
| Impact | Currently under analysis |
| Description | Clatterbridge Cancer Centre - Anna Olsson-Brown |
| Organisation | The Clatterbridge Cancer Centre NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | Establishment of the HYST and MolGen study at CCC. Working with their biobank team |
| Collaborator Contribution | Establishment of the HYST and MolGen study at CCC. Expanding the role of the CCC biobank |
| Impact | Ongoing work |
| Start Year | 2016 |
| Description | Collaboration with Roche |
| Organisation | Roche Pharmaceuticals |
| Country | Global |
| Sector | Private |
| PI Contribution | I developed a PhD fellowship project with Roche as part of the MRC Clinical Pharmacology Fellowship. This involved several discussions and meeting for their input into the project and culminated in me being awarded the MRC fellowship. |
| Collaborator Contribution | Insight into the project and expert opinion on the clinical pharmacology aspect of the project. |
| Impact | This collaboration led to the MRC Clinical Pharmacology fellowship. I will spend 6 months at Roche to learn industry focused clinical pharmacology and work with the bioinformatics team to work on my data of integrating different 'omics' datasets. |
| Start Year | 2017 |
| Description | Definiens |
| Organisation | Definiens AG |
| Country | Germany |
| Sector | Private |
| PI Contribution | Definiens are an image analysis (https://www.definiens.com/io-panel) company who offer a comprehensive immuno-oncology panel with automated machine learning digital analysis with online platform for access to results. My research has provided 100 images of cases of resected non-small cell lung carcinoma (NSCLC) primary sections of tumour stained with SP263 clone for PD-L1 allowing them to refine their automated processes of PD-L1 detection with "real" cases. In addition I have provided up to 5 sections of unstained tissue from each of these cases for use with their immuno-oncology panel and image analysis, the results of which are shared for both this research team and their industry. At least one publication and presentation of results is agreed within a year. |
| Collaborator Contribution | Definiens have provided a substantial discount of the cost of the multi-plex immunohistochemical staining for their propriety immuno-oncology panel and digital image analysis, as well as ongoing access to their portal for results. The outcomes and interpretation of the sections are included in the cost (upfront commercial cost of project would be in excess of 100k, we have agreed a price of 15k) |
| Impact | Collaboration is ongoing. Publication and presentation of findings at conferences is anticipated, at a minimum. |
| Start Year | 2018 |
| Description | Eli |
| Organisation | Protypia |
| Country | United States |
| Sector | Private |
| PI Contribution | Ongoing collaboration with Protypia in which we have devised a project that will look at the proteomic landscape of the tumour microenvironment in non-small cell lung cancer (NSCLC). Specifics are under a NDA at present. |
| Collaborator Contribution | Protypia provide the mass-spectrometry and analysis of the results. Specifics are under a NDA at present. |
| Impact | Work is in early phases, but a publication is expected at a minimum. |
| Start Year | 2019 |
| Description | Immune related Colitis -Anna Olsson-Brown |
| Organisation | King's College London |
| Department | MRC Centre for Transplantation |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Provision of samples. Working in partnership with their research team to conduct flow cytometry analysis on samples related to immune related colitis from oncological immunotherapy. |
| Collaborator Contribution | Working in partnership with the research team to conduct flow cytometry analysis on samples related to immune related colitis from oncological immunotherapy. |
| Impact | Work Ongoing |
| Start Year | 2017 |
| Description | Immunome Protein Array for Autoantibody detection in the circumstance of oncology immunotherapy toxicity (Munir Pirmohamed/ Anna Olsson-Brown) |
| Organisation | Sengenics |
| Country | Singapore |
| Sector | Private |
| PI Contribution | Study design and sample provision for pilot study |
| Collaborator Contribution | provision of specific test for pilot study |
| Impact | pending |
| Start Year | 2016 |
| Description | Immunotherapy Induced Gastrointestinal Immune-related adverse events |
| Organisation | University of Oxford |
| Department | Translational Gastroenterology Unit (TDU) |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Collaboration working on the transcriptomic and cellular changes seen in patients receiving checkpoint inhibitors who have/have not developed colitis |
| Collaborator Contribution | Undertaking flow cytometry and nanostring analysis of samples |
| Impact | Publication currently under review |
| Start Year | 2018 |
| Description | John Radcliffe Hospital, University of Oxford |
| Organisation | John Radcliffe Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | New collaboration adopting current research in vivo model to OrganOx model |
| Collaborator Contribution | Peter Friend has kindly agreed to share research expertise and OrganOx Facilities |
| Impact | ongoing |
| Start Year | 2021 |
| Description | Medical University of Vienna |
| Organisation | Medical University of Vienna |
| Country | Austria |
| Sector | Academic/University |
| PI Contribution | research expertise and clinical samples |
| Collaborator Contribution | Patrick Starlinger has kindly arrange to share their research expertise and clinical samples |
| Impact | ongoing |
| Start Year | 2019 |
| Description | Multiomics |
| Organisation | University of Liverpool |
| Department | Institute of Integrative Biology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Developed the PhD project and collaborated with Institute of Integrative Biology (IIB) to develop the advanced bioinformatics part of the project to integrate proteomic datasets with genomics, epigenomics and transcriptomics. |
| Collaborator Contribution | Expert input into how to write the grant proposal for the MRC fellowship and plan of action. |
| Impact | Obtained the MRC Clinical Pharmacology PhD fellowship. |
| Start Year | 2017 |
| Description | Northern Oncology Collaboration for Healthcare Research (NOTCH) |
| Organisation | Belfast City Hospital |
| Country | United Kingdom |
| Sector | Hospitals |
| PI Contribution | I am currently Vice-Chair of this multicentre research collaboration focused on delivering large scale real world health research and currently lead a project looking into real world incidence and management of immune related adverse events secondary to checkpoint inhibitors |
| Collaborator Contribution | All partners have representative members on a collaboration board. The current Chair is situated in Leeds. All partners contribute to all projects with different leads for different projects at different centres |
| Impact | Poster presentation at NCRI National Cancer Conference |
| Start Year | 2018 |
| Description | Northern Oncology Collaboration for Healthcare Research (NOTCH) |
| Organisation | Leeds Teaching Hospitals NHS Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am currently Vice-Chair of this multicentre research collaboration focused on delivering large scale real world health research and currently lead a project looking into real world incidence and management of immune related adverse events secondary to checkpoint inhibitors |
| Collaborator Contribution | All partners have representative members on a collaboration board. The current Chair is situated in Leeds. All partners contribute to all projects with different leads for different projects at different centres |
| Impact | Poster presentation at NCRI National Cancer Conference |
| Start Year | 2018 |
| Description | Northern Oncology Collaboration for Healthcare Research (NOTCH) |
| Organisation | Newcastle upon Tyne Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | I am currently Vice-Chair of this multicentre research collaboration focused on delivering large scale real world health research and currently lead a project looking into real world incidence and management of immune related adverse events secondary to checkpoint inhibitors |
| Collaborator Contribution | All partners have representative members on a collaboration board. The current Chair is situated in Leeds. All partners contribute to all projects with different leads for different projects at different centres |
| Impact | Poster presentation at NCRI National Cancer Conference |
| Start Year | 2018 |
| Description | Northern Oncology Collaboration for Healthcare Research (NOTCH) |
| Organisation | Sheffield Teaching Hospitals NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am currently Vice-Chair of this multicentre research collaboration focused on delivering large scale real world health research and currently lead a project looking into real world incidence and management of immune related adverse events secondary to checkpoint inhibitors |
| Collaborator Contribution | All partners have representative members on a collaboration board. The current Chair is situated in Leeds. All partners contribute to all projects with different leads for different projects at different centres |
| Impact | Poster presentation at NCRI National Cancer Conference |
| Start Year | 2018 |
| Description | Northern Oncology Collaboration for Healthcare Research (NOTCH) |
| Organisation | The Christie NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am currently Vice-Chair of this multicentre research collaboration focused on delivering large scale real world health research and currently lead a project looking into real world incidence and management of immune related adverse events secondary to checkpoint inhibitors |
| Collaborator Contribution | All partners have representative members on a collaboration board. The current Chair is situated in Leeds. All partners contribute to all projects with different leads for different projects at different centres |
| Impact | Poster presentation at NCRI National Cancer Conference |
| Start Year | 2018 |
| Description | Northern Oncology Collaboration for Healthcare Research (NOTCH) |
| Organisation | The Clatterbridge Cancer Centre NHS Foundation Trust |
| Country | United Kingdom |
| Sector | Public |
| PI Contribution | I am currently Vice-Chair of this multicentre research collaboration focused on delivering large scale real world health research and currently lead a project looking into real world incidence and management of immune related adverse events secondary to checkpoint inhibitors |
| Collaborator Contribution | All partners have representative members on a collaboration board. The current Chair is situated in Leeds. All partners contribute to all projects with different leads for different projects at different centres |
| Impact | Poster presentation at NCRI National Cancer Conference |
| Start Year | 2018 |
| Description | PhD supervision - Prof Mark Coles to Dr Anna Olsson-Brown |
| Organisation | University of Oxford |
| Department | Kennedy Institute of Rheumatology |
| Country | United Kingdom |
| Sector | Academic/University |
| PI Contribution | Anna is Prof Mark Coles PhD student |
| Collaborator Contribution | Prof Mark Coles provides PhD supervision to Dr Anna Olsson-Brown |
| Impact | Poster presentations presented by Anna Olsson-Brown at ISOP and ASCO Immuno-oncology Symposium |
| Start Year | 2016 |
| Description | Sengenic Immunome Protein Array - Anna Olsson-Brown |
| Organisation | Sengenics |
| Country | Singapore |
| Sector | Private |
| PI Contribution | Collection and provision of anonymised samples for investigation into the immune related adverse events following oncological immunotherapy |
| Collaborator Contribution | Evaluation of serum samples using the Immunome protein array platform determining the presence of autoantibodies. They are also providing the data analysis for the sample pilot |
| Impact | No outputs as yet. Collaboration just concluding the initial round of analysis |
| Start Year | 2017 |
| Description | USZ Clinical Pharmacology and Toxicology |
| Organisation | University Hospital Zürich |
| Country | Switzerland |
| Sector | Hospitals |
| PI Contribution | Provided idea of research, big data analytic skills and manpower for conducting the research. Reagents purchased and delivered to collaborator. |
| Collaborator Contribution | Provided refinement of research idea and skill set for liver disease modeling. Contributed in kind with certain reagents that allow conducting of research. Provided discounted accomodation for opportunity to conduct work as a visiting fellow. |
| Impact | Wet lab studies have been conducted and generated data for further hypothesis testing. Collaboration includes clinicians, biostatisticians (drug binding modeling) and wet lab scientists (specialist interest in liver and kidney drug and toxicity and modeling) |
| Start Year | 2022 |
| Description | (*Best HPB Oral Presentation) Pharmacological Stimulation of Nrf2 Enhances Functional Liver Regeneration Following Major Hepatectomy. Association of Upper Gastrointestinal Surgery (AUGIS) 22nd Annual Scientific Meeting 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Chan BKY, Forootan SS, Elmasry M, Bunday TM, Malik HZ, Goldring CE, Copple IM, Fenwick SW. Pharmacological Stimulation of Nrf2 Enhances Functional Liver Regeneration Following Major Hepatectomy. Association of Upper Gastrointestinal Surgery (AUGIS) 22nd Annual Scientific Meeting 2019 - Liverpool, UK. 26 September 2019 (*Best HPB Presentation) |
| Year(s) Of Engagement Activity | 2019 |
| Description | (*William Lloyd-Jones Tankard - Best Presentation) Nrf2 Enhances Liver Regeneration after Hepatectomy. Liverpool & North West Surgical Society (LNWSS) 52nd Annual Meeting 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Chan BKY, Forootan SS, Elmasry M, Bunday TM, Malik HZ, Goldring CE, Copple IM, Fenwick SW. Nrf2 Enhances Liver Regeneration after Hepatectomy. Liverpool & North West Surgical Society (LNWSS) 52nd Annual Meeting 2019 - Liverpool, UK. 6 December 2019 (*William Lloyd-Jones Tankard - Best Presentation) |
| Year(s) Of Engagement Activity | 2019 |
| Description | (Nominated Young Investigator Award) Pharmacological Activation of Nrf2 Enhances Metabolic Remodelling and Functional Liver Regeneration Following Major Hepatectomy. International Hepato-Pancreato-Biliary Association (IHPBA) 14th World Congress 2020 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Chan BKY, Forootan SS, Elmasry M, Bunday TM, Malik HZ, Goldring CE, Copple IM, Fenwick SW. Pharmacological Activation of Nrf2 Enhances Metabolic Remodelling and Functional Liver Regeneration Following Major Hepatectomy. International Hepato-Pancreato-Biliary Association (IHPBA) 14th World Congress 2020 - Melbourne, Australia (Virtual). 27 November 2020 (*Nominated Young Investigator Award - final 12 in 1364 accepted abstracts) |
| Year(s) Of Engagement Activity | 2020 |
| Description | (Poster Presentation) Effectiveness of the Multidisciplinary Team assessment in suspected malignancy and complex gallbladder disease. Association of Upper Gastrointestinal Surgery (AUGIS) 22nd Annual Scientific Meeting 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Carrion-Alvarez L, Chan BKY, Telfer R, Bird N, Mann K, Jones RP, Malik HZ, Fenwick SW, Diaz-Nieto R. Effectiveness of the Multidisciplinary Team assessment in suspected malignancy and complex gallbladder disease. Association of Upper Gastrointestinal Surgery (AUGIS) 22nd Annual Scientific Meeting 2019 - Liverpool, UK. 26 September 2019 |
| Year(s) Of Engagement Activity | 2019 |
| Description | (Poster Presentation) Our Long-Term Outcomes after Surgical Management of Hepatocellular Carcinoma. Association of Upper Gastrointestinal Surgery (AUGIS) 22nd Annual Scientific Meeting 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Rehman AH, Mann K, Pina I, Leader R, Chan BKY, Jones RP, Malik HZ, Fenwick SW, Diaz-Nieto R. Our Long-Term Outcomes after Surgical Management of Hepatocellular Carcinoma. Association of Upper Gastrointestinal Surgery (AUGIS) 22nd Annual Scientific Meeting 2019 - Liverpool, UK. 26 September 2019 |
| Year(s) Of Engagement Activity | 2019 |
| Description | (Poster Presentation) The Impact of Intra-Operative Frozen Section in Managing Suspected Gallbladder Cancer. Association of Upper Gastrointestinal Surgery (AUGIS) 22nd Annual Scientific Meeting 2019 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Chan BKY, Telfer R, Carrion-Alvarez L, Rehman A, Mann K, Jones RP, Malik HZ, Fenwick SW, Diaz-Nieto R. The Impact of Intra-Operative Frozen Section in Managing Suspected Gallbladder Cancer. Association of Upper Gastrointestinal Surgery (AUGIS) 22nd Annual Scientific Meeting 2019 - Liverpool, UK. 26 September 2019 |
| Year(s) Of Engagement Activity | 2019 |
| Description | (Undergraduate Workshop) Pursuing Academia, Liverpool's 4th Annual National Student Research Conference, University of Liverpool |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Undergraduate students |
| Results and Impact | The pursuit of postgraduate research plays a vital role in the progression of all aspects of society and in none more so than biochemistry and medicine. Both Masters and PhD programmes offer students an opportunity to contribute to their field of interest, as well as a chance to broaden employment opportunities. To help navigate applying to and undertaking these competitive courses, LivResCon4 are proud to welcome a team of individuals with recent experience in postgraduate research to discuss the field and any opportunities or pitfalls to look out for! |
| Year(s) Of Engagement Activity | 2019 |
| Description | Antibody responses to SARS-CoV-2 vaccination in patients receiving immunomodulators for immune-mediated inflammatory diseases. Psoriasis Gene to Clinic. London & virtual, 10.12.2021. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral presentation |
| Year(s) Of Engagement Activity | 2021 |
| Description | Atopic polygenic risk score is associated with paradoxical eczema developing in psoriasis patients treated with biologics. European Society for Dermatological Research Annual Meeting, Amsterdam, 30.09.2022. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral presentation |
| Year(s) Of Engagement Activity | 2022 |
| Description | BSAC Standing Committee for Antimicrobial Susceptibility Testing |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | I was elected to take part in this committee from 2023 - 2024. The committee aims to: Support UK laboratories with Antimicrobial Susceptibility testing (AST) problems Provide AST guidance specific to the UK and clarification on EUCAST guidance Support further development of EUCAST susceptibility testing methods Improve quality of susceptibility testing through educational User Group Days & Residential Workshops The impact is as yet unknown as I have only just taken on this role for 2023 -2024. |
| Year(s) Of Engagement Activity | 2023 |
| URL | https://bsac.org.uk/susceptibility/ |
| Description | British Society of Gastroenteorology Annual Conference (Live 2022) - 8 selected oral abstracts for the liver - Genome wide analysis identifies potential mechanisms of non-alcoholic fatty liver disease |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | The purpose was to present and disseminate research conducted to professionals regarding potential disease related pathophysiological mechanisms from our genome-guided analysis. Around 100-500 individuals were in the room of this parallel ran session of the conference. This had a 5 minutes Q&A session and subsequently lead to private discussion with a few individuals who were interested in the research and exchange of ideas. |
| Year(s) Of Engagement Activity | 2022 |
| Description | CDSS workshop presentation: Overview of safety profile of immune-stimulating agents - Anna Olsson-Brown |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Anna gave a presentation regarding the evolving safety concerns of immune checkpoint blockade and some initial early signals regarding pathology/ toxicity |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://www.bionow.co.uk/events/safetyofimmunecheckpointinhibitors.aspx |
| Description | Checkpoint inhibitor induced thyroid immune related adverse events; ISOP poster -Anna Olsson-Brown |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Anna presented a poster at this international meeting |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://isop2017liverpool.org/ |
| Description | Conference: Health is Wealth (Dr Anna Olsson-Brown) |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | To share information. Stimulated panel debate within the session. |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.liverpoollep.org/events/health-wealth-2017-conference/ |
| Description | Dermatology patient focus group |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Set up dermatology research focus group in Mersey area to discuss potential studies of interest and to refine studies in place. Stimulate discussion between clinicians, patients and research team. |
| Year(s) Of Engagement Activity | 2018 |
| Description | ISOP Oral Presentation: Pharmacovigilance of anti-cancer medicines: opportunities and - Anna Olsson-Brown |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Anna gave anoral presentation reviewing the incidence and impact of immune related adverse events associated with immune checkpoint inhibitors. Talk given on Wednesday 18/10/18 at this international conference |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://isop2017liverpool.org/programme/ |
| Description | Interview for BBC |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Raised general awareness of the research and clinical services we have established for the management of immune related adverse events |
| Year(s) Of Engagement Activity | 2018 |
| Description | Invited Speaker at the ACP Immunotherapy Workshop |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Research and early phase trials in Immunotherapy: Challenges and Innovations. Invited Oral Presentation. Association of Cancer Physicians Immunotherapy Workshop. (December 2018) |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://www.theacp.org.uk/userfiles/file/calendar/2018/acp-immunotherapy-workshop-2018_-draft-agenda-... |
| Description | Liverpool public engagement activity - "Skin, Bone and Guts: Our Science" |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Approximately 50 people attended an evening session on 15 March 2022 in Liverpool consisting of presentations and activities, run by MRC-funded PhD students from the Universities of Liverpool, Manchester and Newcastle. Presentations were focussed in describing the results and importance of the students' work in an accessible manner. Activities included the use of virtual reality and ultraviolet responsive materials to discuss matters pertaining to public health. |
| Year(s) Of Engagement Activity | 2022 |
| Description | MRC Annual Showcase , Manchester - 15th May 2019 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | MRC Annual Showcase for PhD Fellows to present their current activity/portfolio to supervisors and a wider audience. Approximately 50 delegates attended and three external speakers showcasing the work of the MRC Fellowship. |
| Year(s) Of Engagement Activity | 2019 |
| Description | MRC Fellowship Scheme Annual Showcase |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | to Showcase the research undertaken by clinical fellows on the NW MRC Fellowship programme |
| Year(s) Of Engagement Activity | 2021 |
| Description | MRC Festival |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | MRC Science Festival - this was a showcase event of MRC funded projects aiming to better describe them to the public and othe researchers in the university. |
| Year(s) Of Engagement Activity | 2019 |
| Description | MRC Festival - Behind the Headlines - 19th June 2019 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | A group of staff from the Institute of Ageing and Chronic Disease's CIMA, in partnership with the NWE MRC Fellowship Scheme in CPT, held a unique event at the Brink Café in Liverpool last month, aimed at debunking some of the sometimes exaggerated headlines that we see in the newspapers and online. Researchers, students and senior staff from the IACD were each tasked with selecting a headline, online article, or other media source which highlighted a story linked to their area of research and then stripping away the hyperbole and spin, to reveal the true facts about the science. Six presentations were made in total, covering topics such as Cancer treatment, Antioxidant supplements and skincare myths, giving the audience a chance to hear from those who are working at the cutting edge of these fields on what is the truth and what is Fake News. Attendees were also given the opportunity to take part in a Q and A after each presentation to try to address any additional questions and uncertainties they may have on the subject. The event was well received, with over 25 people signing up to attend, and was part of the MRC festival of Science week. |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://mrc.ukri.org/about/getting-involved/mrcfestival/ |
| Description | MRC Festival of Science "Ask a Scientist"/"Im a Scientist, Get me Out of Here) |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Schools |
| Results and Impact | Throughout the month of June participated in an online series of questions and live chat sessions that allowed school children from around the country to ask a variety of questions to scientists and to discuss matters of varying topics. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://mrcfestival2018.imascientist.org.uk |
| Description | MRC Pint of Science Festival |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Public/other audiences |
| Results and Impact | Dr Alex Haragan and Dr Ben Chan participated in the 'Pint of Science Festival' which is an annual Festival which takes place in cities across the world in May, and sees brilliant scientists chat about their latest research with the public in a pub! In 2019 the festival will run from Monday 20 to Wednesday 22 May. This is the third year of Pint of Science Liverpool. All previous events have sold out, with over 1000 members of the public attending events, and over 90 staff and students taking part! |
| Year(s) Of Engagement Activity | 2019 |
| URL | https://www.liverpool.ac.uk/health-and-life-sciences/public-engagement/getinvolved/ |
| Description | Macmillan Primary Care Conference: Immunotherapy workshop - Anna Olsson-Brown |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Anna held an workshop highlighting and raising the profile of immunotherapy toxicity (so called immune related adverse events) |
| Year(s) Of Engagement Activity | 2017 |
| Description | Manchester Science Spectacular 2017 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Clinical Research Fellows on the North West England MRC Fellowship Scheme joined with several PhD students from the MRC Centre for Drug Safety Science to take part in the 2017 University of Manchester Science Spectacular, an annual event that forms part of the Manchester Science Festival. The Research Fellows and the PhD students ran an activity stand called 'Marvellous Medicine' which explained a little bit about where drugs come from and how clinicians make decisions about how to use them. However the main focus of this year's activity was to explain the use of immunotherapy in treating cancer using a skittles game. The Science Spectacular is normally attended by approx. 1,500 people and we estimate that approximately 100 guests visited the activity stand. The verbal feedback we received on the day from both adults and children was very positive. |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://www.engagement.manchester.ac.uk/highlights/manchester_science_festival/science_spectacular/ |
| Description | Manchester Science Spectacular 2018 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | The Manchester Science Spectacular is an annual event that forms part of the Manchester Science Festival. In 2018 six of the scheme's Fellows took part in this event (Sara Boyd, Umair Khan, Jing Xu, Christopher Darlow, Alexander Haragan and Kim Su). The Fellows ran table top activities aimed at a family audience which sought to explain personalised medicine and immunotherapy. The science spectacular attracted well over a thousand visitors and between 100 and 150 people visited the 'Marvellous Medicine' stand. Children and their parents enjoyed the activities and many asked several questions. |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://www.engagement.manchester.ac.uk/highlights/manchester_science_festival/science_spectacular/ |
| Description | Media release in the huffington post |
| Form Of Engagement Activity | A press release, press conference or response to a media enquiry/interview |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Public/other audiences |
| Results and Impact | Publication in the Huffington Post to raise awareness of immunotherapy treatment, toxicities and management |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.huffingtonpost.co.uk/entry/exclusive-i-thought-i-wouldnt-see-another-christmas-but-mirac... |
| Description | Member of the organising committee and sessional chair: Early researcher Symposium - Anna Olsson-Brown |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Postgraduate students |
| Results and Impact | Anna was a member of the scientific committee and chair of the Personalised Medicine and Drug Safety session. Assessment and decisions regarding abstracts and invites to poster and oral presenters. Running of the session on the day. Member of the judging panel for oral and poster presentation, |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://ecslivuni.wordpress.com/scientific-committee/ |
| Description | NHS 70 Event (Alexander Haragan, Umair Khan and Anna Olsson Brown) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Public/other audiences |
| Results and Impact | As part of the 70th Anniversary of the NHS the local NHS Trust invited researchers to set up information stands in communal areas of the hospital to provide an opportunity for patients and members of the public to learn more about medical research that is happening locally. Three Liverpool based Fellows took part in this event and spoke to members of the pubic about advances in cancer medicine (Immunotherapy) and personalised health. Participants were also able to play a table top bowling game which acted as a metaphor for how immunotherapy works and this was very well received with several participants saying it had really helped them to understand the concept. |
| Year(s) Of Engagement Activity | 2018 |
| Description | NWCRC Seminar Series |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Other audiences |
| Results and Impact | A talk as part of the North West Cancer Research Centre (NWCRC) seminar series entitled ""Immunotherapy in cancer treatment - current successes and future perspectives" This reached local and regional students, academics, researchers and medical professionals. Much debate was generated./ |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://www.liverpool.ac.uk/nwcrc/events/ |
| Description | North West GI Conference 2022 - Oral Presentation - Genome wide analysis reveals potential mechanisms associated with non-alcoholic fatty liver disease |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Professional Practitioners |
| Results and Impact | Selected as 1 of 5 oral presentations delivered over a duration 12 minutes with 3 minutes Q&A. This lead to informal discussion afterwards with a few clinicians in the region and academic staff from the North West. |
| Year(s) Of Engagement Activity | 2022 |
| Description | Oral presentation at ECCMID 2021 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral presentation at ECCMID 2021 - "Pharmacodynamics of fosfomycin and flomoxef combination therapy for neonatal sepsis modelled in a hollow-fibre infection model" |
| Year(s) Of Engagement Activity | 2021 |
| Description | Oral presentation at ECCMID 2022 |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Policymakers/politicians |
| Results and Impact | 10min Oral presentation at ECCMID 2022 - "Assessment of flomoxef and amikacin in a hollow-fibre infection model for the potential empiric treatment of neonatal sepsis in low- and middle-income settings" |
| Year(s) Of Engagement Activity | 2022 |
| Description | Organisation of Seminar from External Speakers - Sengenics (Dr Anna Olsson-Brown; Dr Neil French) |
| Form Of Engagement Activity | Participation in an open day or visit at my research institution |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Postgraduate students |
| Results and Impact | To share information. Stimulated debate and questions within the attendees. |
| Year(s) Of Engagement Activity | 2017 |
| Description | Organiser of CDSS workshop: Safety of immune checkpoint inhibitors - Anna Olsson-Brown |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | cAnna was the o-organiser of CDSS workshop on safety of immune-oncology agents. Involved in programme development, inviting speakers and running of the event |
| Year(s) Of Engagement Activity | 2018 |
| URL | http://www.bionow.co.uk/events/safetyofimmunecheckpointinhibitors.aspx |
| Description | Paradoxical atopic eczema in a man using biologic therapy for psoriasis. Royal Society of Medicine Dermatology Meeting. Virtual 19.11.2020. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral presentation |
| Year(s) Of Engagement Activity | 2020 |
| Description | Participation in a advisory committee - Dr Boyd is a member of the JRCPTB Specialty Advisory Committee for Infection Training in the UK (2016-2020) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Participation in a advisory committee - Dr Boyd is a member of the JRCPTB Specialty Advisory Committee for Infection Training in the UK (2016-2020). This committee meets several times per year to discuss the training of Infectious Diseases and Microbiology clinicians. Dr Boyd is enabled to represent the views of her peers and also to inform key decision makers in Infection training. She is enabled to advocate for research training for all infection trainees, which will lead to greater societal benefit and a more capable clinical workforce. |
| Year(s) Of Engagement Activity | 2016,2017,2018,2019 |
| Description | Participation in a professional council - Dr Boyd is a the trainee representative for the British Infection Association in the UK (2016-2020) |
| Form Of Engagement Activity | A formal working group, expert panel or dialogue |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Dr Boyd is the trainee representative for the British Infection Association. This role allows her to debate and advocate for the BIA (a registered charity) to fund medical research and it also allows her to partake in organising conferences and public involvement areas, for example she administrates the BIA twitter page. These activities have wide reach and allow her to disseminate research findings and influence decision making at a high level. |
| Year(s) Of Engagement Activity | 2016,2017,2018,2019,2020 |
| Description | Participation on a media video regarding medical oncology - Anna Olsson-Brown |
| Form Of Engagement Activity | Engagement focused website, blog or social media channel |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Anna Participated in media video regarding a career in medical oncology |
| Year(s) Of Engagement Activity | 2017 |
| URL | http://ecancer.org/video/6359/why-choose-medical-oncology--trainee-perspective.php |
| Description | Pint of Science |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Public/other audiences |
| Results and Impact | Pint of Science is a non-profit organisation that brings scientists to local pubs to discuss their latest research and findings with you. I was one of 3 speakers talking in the broader theme of "Our Body" and talked with an audience of varied and wide background of the specifics of my project and how immunotherapy changes and is changing medical and oncological care, and how my project and these related schemes are actively benefiting the wider public and improving this care. After my 25 minute presentation on the talk I took a Q&A session and over the rest of the evening fielded more questions from interested attendees. |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://pintofscience.co.uk |
| Description | Poster Presentation at NCRI - NOTCH Collaboration |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Jones C, Olsson-Brown A, Gault A et al. The Northern Oncology Trainees Collaborative for Healthcare Research. Poster Presentation National Cancer Research Institute Annual Conference. (November 2018) |
| Year(s) Of Engagement Activity | 2018 |
| Description | Poster Presentation at NCRI on irAE Colitis |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Olsson-Brown A, Sacco J, Corrie P, Steven N et al. A National Snapshot of real-world combination checkpoint inhibitor induced immune-related colitis. Poster Presentation National Cancer Research Institute Annual Conference. (November 2018) |
| Year(s) Of Engagement Activity | 2018 |
| Description | Poster presentation at ECCMID 2021 |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presentation at ECCMID 2021 - "Pharmacokinetics/pharmacodynamics of antibacterial drugs & therapeutic drug monitoring" |
| Year(s) Of Engagement Activity | 2021 |
| Description | Poster presentation at ECCMID 2022 (1) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presentation at ECCMID 2022: 1) "Using novel physiology-based pharmacokinetic models to predict adequate drug exposures of fosfomycin and amikacin in combination to treat neonatal sepsis" |
| Year(s) Of Engagement Activity | 2022 |
| Description | Poster presentation at ECCMID 2022 (2) |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Poster presentation at ECCMID 2022: "Insights into the neonatal pharmacokinetic characteristics of flomoxef using physiology-based pharmacokinetic modelling" |
| Year(s) Of Engagement Activity | 2022 |
| Description | Poster presentation at ESMO immuno-oncology congress |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presented a poster on a nationwide audit about outcomes of patients with GI toxicity secondary to immunotherapy |
| Year(s) Of Engagement Activity | 2022 |
| URL | https://oncologypro.esmo.org/meeting-resources/esmo-immuno-oncology-congress/treatment-and-outcomes-... |
| Description | Poster presentation at the ASCO SITC Clinical Immuno-Oncology Symposium: Two distinct clinical trajectories of inflammatory thyroiditis evoked by checkpoint blockade in malignant melanoma - Anna Olsson-Brown |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Anna presented a poster to the entire delegation on Thursday 25th January 2018 at the international immune-oncology symposium at the Mariott Hotel, San Francisco |
| Year(s) Of Engagement Activity | 2018 |
| URL | https://meetinglibrary.asco.org/browse-meetings/2018%20ASCO-SITC%20Clinical%20Immuno-Oncology%20Symp... |
| Description | Presentation at LUPUS International Meeting |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral presentation at LUPUS 2021, online conference, October 2021. Early risk of infection in SLE patients treated with Rituximab: Results from the British Isles Lupus Assessment Group Biologics Registry (BILAG-BR). Awarded • LUPUS 2021 congress Top 6 LUPUS 2021 Abstracts prize, October 2021 (International) |
| Year(s) Of Engagement Activity | 2021 |
| Description | Presentation at SLEuro |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Presentation on Determinants of health-related quality of life across the spectrum of systemic autoimmune rheumatic diseases: Results from the LEAP cohort. Oral poster presentation at SLEuro, Stockholm, Sweden. May 2022 |
| Year(s) Of Engagement Activity | 2022 |
| Description | Risk factors for paradoxical eczema in patients with psoriasis on biologics: a nested case-control study. British Association of Dermatologists 102nd Annual Meeting, Glasgow, 07.07.2022. |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | International |
| Primary Audience | Professional Practitioners |
| Results and Impact | Oral presentation awarded research prize |
| Year(s) Of Engagement Activity | 2022 |
| Description | Sjogren's Group PPIE |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | 20-30 patients with Sjogren's syndrome, I presented on my PhD research project to the group which was then discussed with questions and answer session. As a result, there was significant interest in my study with several patients asking to enroll. Some of the discussion will inform future research plans. |
| Year(s) Of Engagement Activity | 2021 |
| Description | UKONS National Conference - Poster Presentation - Anna Olsson-Brown |
| Form Of Engagement Activity | A talk or presentation |
| Part Of Official Scheme? | No |
| Geographic Reach | National |
| Primary Audience | Professional Practitioners |
| Results and Impact | Anna was the co-author of a poster presentation - Abstract 7 Developing guidelines to standardise the management of immunotherapy toxicities. Upoton J, Olsson-Brown A |
| Year(s) Of Engagement Activity | 2017 |
| URL | https://rcni.com/sites/rcn_nspace/files/UKONS%20booklet%202017%20WEB%20FINAL.pdf |
| Description | Wikipedia Event - A Level students |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Schools |
| Results and Impact | Engagement with local schools, A Level Students participated in activity. The event entitled 'A celebration of Women in Science'; Wikipedia edit-a-thon, involved 21 A Level students working with five female scientists to edit the Wikipedia pages of female scientists past and present. The event was supported by Wikimedia and Dr Jess Wade who provided tuition to the students and academic staff in how to edit Wikipedia. Female academic scientist also gave inspirational talks to the students. The activity was part of the University of Liverpool's Athena Swan agenda and was organised by Angela Foxcroft (Fellowship Scheme Co-ordinator) and Dr Lauren Walker (Former fellow of the Fellowship Scheme). |
| Year(s) Of Engagement Activity | 2018 |
| Description | Workshop on improving equality, inclusion and diversity in research |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Regional |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | Diverse voices workshop aimed at improved inclusion in participation in research for people from diverse backgrounds |
| Year(s) Of Engagement Activity | 2023 |
| Description | World Cancer Day Public engagement |
| Form Of Engagement Activity | Participation in an activity, workshop or similar |
| Part Of Official Scheme? | No |
| Geographic Reach | Local |
| Primary Audience | Patients, carers and/or patient groups |
| Results and Impact | As part of world cancer day, a stall about research activity was set up by University of Liverpool. I volunteered where using a mini bowling set game demonstrated the concept of drug resistance to patients. We also had general discussion about the research I carry out and general direction of research. |
| Year(s) Of Engagement Activity | 2019 |